Comparison of Centurion® Vision System With Balanced Tip and the Infiniti® Vision System With the Mini Flared Kelman (MFK) Tip During Cataract Extraction Surgery of Hard Lenses

Cataracts Clinical Trial

Official title:

Comparison of Cumulative Dissipated Energy (CDE) and Balanced Salt Solution (BSS) Fluid Used With the Centurion® With the 45° Degree Balanced Ultrasound (U/S) Tip vs the Centurion® With Mini Flared Kelman U/S Tip vs the Infiniti® With Mini Flared Kelman U/S Tip on Hard Lenses

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02502526
• Other study ID #: CTU424-P001
• Status: Completed
• Phase: N/A
• Start date: July 27, 2015
• Est. completion date: November 30, 2017

Study information

• Verified date: April 2018
• Source: Alcon Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate that the Centurion® Vision System (CVS) used with the 45° Balanced Tip will result in less Cumulative Dissipated Energy (CDE) than the lnfiniti® Vision System (IVS) used with the 45° Mini-Flared Kelman (MFK) tip during cataract extraction surgery via phacoemulsification of cataract grades NII- NIV [Lens opacities classification system II (LOCSII)].

Recruitment information / eligibility

• Status: Completed
• Enrollment: 231
• Est. completion date: November 30, 2017
• Est. primary completion date: March 23, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Willing and able to consent for participation;

• Willing and able to attend postoperative examinations per protocol schedule;

• Cataract in at least one eye with a Nuclear Opalescence of II-IV (via LOCSII) followed by posterior chamber intraocular lens (IOL) implantation;

• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Planned multiple procedures, including Laser Phaco, LASIK, LRI's etc. during surgery or the course of this study;

• Severe conditions of acute or chronic diseases or illnesses that would increase the operative risk or confound the result of this investigation;

• Untreated or uncontrolled Glaucoma;

• Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes;

• Poorly dilating pupil or other pupil defect;

• Current or previous use of an alpha-1-selective adrenoceptor blocking agent or antagonist of alpha 1A adrenoceptor (eg, Flomax®, Hyntrin®, or Cardura®);

• Severe retinal disorders;

• Corneal disease or retinal detachment;

• Other protocol-specified exclusion criteria may apply.

Related Conditions & MeSH terms

• Cataract
• Cataracts

Intervention

Device:
• Centurion® Vision System, 45° Balanced Tip

• Centurion® Vision System, 45° MFK Tip

• lnfiniti® Vision System, 45° MFK Tip

• INTREPID® Ultra infusion sleeve

• Ultra infusion sleeve

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Alcon Research

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative Dissipated Energy (CDE)	Cumulative Dissipated Energy (CDE) represents the energy dissipated of the u/s tip and infusion sleeve at the incision point (5.6mm back from the cutting edge of the tip) during the removal of cataractous lens. CDE was reported on the Vision System interface and measured in percent-seconds. A lower CDE indicates that less energy was present at the incision site. Only one eye (study eye) contributed to the analysis. This outcome measure was pre-specified for CVS Bal and IVS MFK.	Day 0 (operative day)
Secondary	Cumulative Dissipated Energy (CDE)	Cumulative Dissipated Energy (CDE) represents the energy dissipated of the u/s tip and infusion sleeve at the incision point (5.6mm back from the cutting edge of the tip) during the removal of cataractous lens. CDE was reported on the Vision System interface and measured in percent-seconds. A lower CDE indicates that less energy was present at the incision site. Only one eye (study eye) contributed to the analysis.	Day 0 (operative day)
Secondary	Balanced Salt Solution (BSS) Fluid Used	BSS Fluid was measured by weighing the BSS bag after priming. BSS Used is Incision Leakage Fluid plus Aspiration Fluid Used. A reduction in BSS fluid used implies less induced trauma to tissues. Only one eye (study eye) contributed to the analysis.	Day 0 (operative day)

External Links

•   Results from the Novartis Clinical Trial Results Website